Kura Oncology, Inc.

KURA

Pharmaceutical Preparations

Mkt Cap

$1.637B

PE

-9.74

Debt

$9.376M

Cash

$41.51M

EV

$1.605B

FCF

-$138M

Market Cap

$1.637B

P/E Ratio

-9.74

Debt

$9.376M

Cash

$41.51M

EV

$1.605B

FCF

-$138M

Charts data: {"Earnings":[{"time":"2014-12-30","value":-204691},{"time":"2015-12-30","value":-22625000},{"time":"2016-12-30","value":-27560000},{"time":"2017-12-30","value":-35434000},{"time":"2018-12-30","value":-60447000},{"time":"2019-12-30","value":-63140000},{"time":"2020-12-30","value":-89625000},{"time":"2021-12-30","value":-130466000},{"time":"2022-12-30","value":-135840000},{"time":"2023-12-30","value":-152631000}],"Sales":[],"Net Margins":[],"Assets":[{"time":"2014-12-30","value":5613},{"time":"2015-12-30","value":87259000},{"time":"2016-12-30","value":69821000},{"time":"2017-12-30","value":95851000},{"time":"2018-12-30","value":182379000},{"time":"2019-12-30","value":241972000},{"time":"2020-12-30","value":647212000},{"time":"2021-12-30","value":534051000},{"time":"2022-12-30","value":456306000},{"time":"2023-12-30","value":448935000}],"Stockholders Equity":[{"time":"2014-12-30","value":-154691},{"time":"2015-12-30","value":82103000},{"time":"2016-12-30","value":56876000},{"time":"2017-12-30","value":79865000},{"time":"2018-12-30","value":160985000},{"time":"2019-12-30","value":218781000},{"time":"2020-12-30","value":610905000},{"time":"2021-12-30","value":506609000},{"time":"2022-12-30","value":420278000},{"time":"2023-12-30","value":397273000}],"ROE":[{"time":"2014-12-30","value":1.3232250098583629},{"time":"2015-12-30","value":-0.27556849323410837},{"time":"2016-12-30","value":-0.48456290878402136},{"time":"2017-12-30","value":-0.44367369936768297},{"time":"2018-12-30","value":-0.3754821877814703},{"time":"2019-12-30","value":-0.2885991013844895},{"time":"2020-12-30","value":-0.14670857170918555},{"time":"2021-12-30","value":-0.25752799496258455},{"time":"2022-12-30","value":-0.323214634123128},{"time":"2023-12-30","value":-0.3841967614209876}],"ROA":[{"time":"2014-12-30","value":-32.19116337074648}]}

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19
10-Q
3/31/19
10-K
12/31/18
10-Q
9/30/18
10-Q
6/30/18
10-Q
3/31/18
10-K
12/31/17

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Data are missing

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-	-	-	-	-	-	-	-	-	-
ROA	-	-	-	-	-	-	-	-	-	-
ROE	-28%	-48%	-44%	-38%	-29%	-15%	-26%	-32%	-38%	-33%

What is the average Net Margin?

The average Net Margin over the past 5 years is -.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -29.6%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -0.74%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Under the assumption that FCF does not diminish and debt does not increase, the current years to repay the debt are acceptable.

Data are missing

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-	-	-	-	-	-0.08	-0.07	-0.07
Debt Equity	-	0.13	0.11	0.05	0.04	0.02	-	0.02	0.02	0.02
MIN
Graham Stability	-	-	-	-	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -0.07.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is 0.01.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2016	12-2018	12-2020	12-2022	Trend
Revenue	-	-	-	-	-
Net Income	-	-	-	-	-
Stockholders Equity	32%	20%	-13%	-5.5%	-3.8%
FCF	-	-	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +20.35%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +19.8%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -3.85%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.